Literature DB >> 31238357

Updates in Red Blood Cell and Platelet Transfusions in Preterm Neonates.

Enrico Lopriore1.   

Abstract

Anemia and thrombocytopenia occur frequently in preterm neonates and the majority of them require at least one blood transfusion during the first few weeks of life. However, there is no international consensus on optimal transfusion management neither for red blood cell nor for platelet transfusions, resulting in large worldwide variations in transfusion practices between neonatal intensive care units. In the past decade, several studies performed in adults, infants as well as neonates showed that restrictive transfusion guidelines are just as safe as liberal guidelines. In fact, some studies even showed that liberal guidelines could be associated with an increased risk of morbidity and mortality, suggesting that too many transfusions may have a deleterious effect. In a recent randomized trial in preterm neonates with thrombocytopenia, the liberal transfusion group (receiving more platelet transfusions) had a significantly higher rate of death or major bleeding than the restrictive group (receiving less transfusions). In preterm neonates with anemia, the available evidence is also limited and controversial. Two large randomized controlled trials (ETTNO and TOP) are currently assessing the safety and effectiveness of liberal versus restrictive red blood cell transfusions. Results of these large two studies, including the long-term neurodevelopment outcome, are eagerly awaited. Until then, reduction of anemia of prematurity by implementation of effective preventive measures, such as delayed cord clamping and minimization of iatrogenic blood loss, remain of paramount importance. Thieme Medical Publishers 333 Seventh Avenue, New York, NY 10001, USA.

Entities:  

Mesh:

Year:  2019        PMID: 31238357     DOI: 10.1055/s-0039-1691775

Source DB:  PubMed          Journal:  Am J Perinatol        ISSN: 0735-1631            Impact factor:   1.862


  7 in total

1.  Evaluation of the Effect of Blood Transfusion on Retinopathy of Prematurity at a Tertiary Care Center in Western Saudi Arabia.

Authors:  Lina H Raffa; Wasayf Aljohani
Journal:  Cureus       Date:  2022-04-26

Review 2.  Anemia of prematurity: how low is too low?

Authors:  Catherine C Cibulskis; Akhil Maheshwari; Rakesh Rao; Amit M Mathur
Journal:  J Perinatol       Date:  2021-03-04       Impact factor: 3.225

3.  Transfusion prevention using erythropoietin, parenteral sucrose iron, and fewer phlebotomies in infants born at ≤30 weeks gestation at a high altitude center: a 10-year experience.

Authors:  Angela B Hoyos; Pablo Vasquez-Hoyos
Journal:  J Perinatol       Date:  2021-02-10       Impact factor: 3.225

4.  Platelet transfusion for neonates with thrombocytopaenia: protocol for a systematic review.

Authors:  Dengjun Liu; Jinlin Wu; Tao Xiong; Yan Yue; Jun Tang
Journal:  BMJ Open       Date:  2020-10-16       Impact factor: 2.692

5.  Effect of early prophylactic low-dose recombinant human erythropoietin on retinopathy of prematurity in very preterm infants.

Authors:  Huiqing Sun; Juan Song; Wenqing Kang; Yong Wang; Xiantao Sun; Chongchen Zhou; Hong Xiong; Falin Xu; Mingchao Li; Xiaoli Zhang; Zengyuan Yu; Xirui Peng; Bingbing Li; Yiran Xu; Shan Xing; Xiaoyang Wang; Changlian Zhu
Journal:  J Transl Med       Date:  2020-10-19       Impact factor: 5.531

6.  Platelet Counts and Patent Ductus Arteriosus in Preterm Infants: An Updated Systematic Review and Meta-Analysis.

Authors:  Gema González-Luis; Stefano Ghiradello; Pilar Bas-Suárez; Giacomo Cavallaro; Fabio Mosca; Ronald I Clyman; Eduardo Villamor
Journal:  Front Pediatr       Date:  2021-01-20       Impact factor: 3.418

7.  Peri-operative red blood cell transfusion in neonates and infants: NEonate and Children audiT of Anaesthesia pRactice IN Europe: A prospective European multicentre observational study.

Authors:  Alexander Fuchs; Nicola Disma; Katalin Virág; Francis Ulmer; Walid Habre; Jurgen C de Graaff; Thomas Riva
Journal:  Eur J Anaesthesiol       Date:  2022-03-01       Impact factor: 4.330

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.